Skip Nav Destination
Issues
1 February 2012
-
Cover Image
Cover Image
The cover image is a screenshot from an experiment used in an agent-based model of ecological dispersal theory applied to neoplastic progression. Resource limitation is an unavoidable consequence of exponential growth and thus a universal limitation on survival and reproduction within ecological systems. Intensive resource use generates competition tending to favor individuals who can escape resource limitation through dispersal. The model (constructed in Netlogo 4.0.2) tested whether high resource use through cell metabolism promotes the evolution of cell motility, in turn selecting for cancer cells with a dispersal phenotype allowing them to find resources in spite of local scarcity. The experiment on the cover introduced metabolically altered “neoplastic” cells (blue borders) into a population of “normal” cells (yellow-green borders). Higher (light red) and lower (dark red) concentrations of microenvironmental resources are reflected in the inter-cell spaces. The consumption, or metabolic, rate is 1.5-fold greater in neoplastic than in normal cells. As shown in this screenshot, an increasing number of neoplastic cells appeared at a middle time point of the experiment, throughout which neoplastic cells (i.e., cells with a higher metabolic rate) evolved higher rates of motility while the motility rate of normal cells remained low (not shown). This work suggests that an evolutionary, ecological framework can provide insights into the transition of benign to invasive and metastatic cells. See article by Aktipis, Maley, and Pepper (beginning on page 266) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspective
Reviews
A Review of Cancer in U.S. Hispanic Populations
Robert W. Haile; Esther M. John; A. Joan Levine; Victoria K. Cortessis; Jennifer B. Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L. Tucker; Jonine L. Bernstein; Thomas E. Rohan; Gloria Y.F. Ho; Melissa L. Bondy; Maria Elena Martinez; Linda Cook; Mariana C. Stern; Marcia Cruz Correa; Jonelle Wright; Seth J. Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R. Monroe; Christopher A. Haiman; Brian E. Henderson; Duncan C. Thomas; Paolo Boffetta
Minireview
Research Articles
Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer
Banu Arun; Vicente Valero; Diane Liu; Abenaa Brewster; Marjorie Green; Angelica Gutierrez-Barrera; Ugur Akar; Edgardo Rivera; Francisco J. Esteva; Aman U. Buzdar; Gabriel N. Hortobagyi; Nour Sneige
Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities
Mike M. Nguyen; Frederick R. Ahmann; Raymond B. Nagle; Chiu-Hsieh Hsu; Joseph A. Tangrea; Howard L. Parnes; Mitchell H. Sokoloff; Matthew B. Gretzer; H-H. Sherry Chow
Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
Seema A. Khan; Robert T. Chatterton; Nancy Michel; Michelle Bryk; Oukseub Lee; David Ivancic; Richard Heinz; Carola M. Zalles; Irene B. Helenowski; Borko D. Jovanovic; Adrian A. Franke; Maarten C. Bosland; Jun Wang; Nora M. Hansen; Kevin P. Bethke; Alexander Dew; Margerie Coomes; Raymond C. Bergan
Cancer Risks for the Relatives of Colorectal Cancer Cases with a Methylated MLH1 Promoter Region: Data from the Colorectal Cancer Family Registry
A. Joan Levine; Aung Ko Win; Daniel D. Buchanan; Mark A. Jenkins; John A. Baron; Joanne P. Young; Tiffany I. Long; Daniel J. Weisenberger; Peter W. Laird; Rebecca L. McCall; David J. Duggan; Robert W. Haile
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.